Organon & Co. (NYSE: OGN)
Health Care · Pharmaceuticals · US
$13.75
0.00% today · +51.8% 1Y
Organon & Co. (NYSE: OGN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.61B and employs 10,000 people.
Over the last twelve months the share price has gained 51.8%, trading between 5.69 and 13.74.
Tweenvest scores Organon & Co. across four factors: quality 51/100, value 61/100, growth 0/100, dividend 83/100. Its strongest factor is dividend.
OGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.61B
- Revenue (TTM)
- $6.13B
- P/E
- 17.34
- EPS
- 0.79
- Dividend yield
- 0.58%
- Beta (5Y)
- 1.52
- 52-week high
- $13.74
- 52-week low
- $5.69
- Avg volume (3M)
- —
- Shares outstanding
- 262.61M
- Employees
- 10,000
- Next earnings
- —
About Organon & Co.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
- ISIN
- US68622V1061
- Founded
- 1923
- Listed since
- May 14, 2021
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,231.78 | -0.15% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $272.81 | -0.12% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF371.90 | -0.51% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.29 | -1.18% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.